Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the safety of the medicine eptacog alfa in women in India who experience severe heavy bleeding after giving birth, known as severe postpartum haemorrhage PPH. The study focuses on women aged 18 years or older who have given birth after 27 weeks of pregnancy and have PPH that does not respond to standard uterotonic treatments. The goal is to gather more knowledge about how safe eptacog alfa is when used for this purpose. Participants will receive a single intravenous bolus injection of eptacog alfa NovoSeven to help stop the bleeding. If the first dose does not stop the bleeding, an additional dose may be given. This study is a Phase IV interventional trial conducted with a single treatment group and will last about 30 to 35 days for each participant. During the study, participants will be monitored for any thromboembolic events from the start of treatment through 30 days after. Researchers will also track serious adverse events, allergic reactions, and any medication errors at baseline and throughout the study period. The study involves careful observation and safety monitoring to understand the effects of eptacog alfa in these women.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with type 2 diabetes T2D who participate in fasting during the month of Ramadan. This Phase 3b, open-label study involves participants between 18 and 65 years old with T2D, aiming to understand how the drug performs in this fasting population. Participants will receive orforglipron orally as the study treatment. The study is a single-arm design without placebo control, and it takes place across multiple countries and centers. Each participants involvement lasts up to 48 weeks and includes both in-clinic and virtual visits. During the study, participants will attend a minimum of 7 clinic visits and 4 virtual visits. Researchers will monitor changes in hemoglobin A1c HbA1c levels from baseline through up to 8 weeks after the start of Ramadan fasting. Other assessments include fasting serum glucose, body weight, and quality of life measures. The study tracks safety and efficacy outcomes throughout the participation period.
Actively Recruiting
Researchers are evaluating centhaquine citrate LYFAQUIN1, a novel drug being studied as a resuscitative agent for adults with hypovolemic shock, which is a life-threatening condition caused by severe blood or fluid loss. This phase IV, open-label, multi-center study aims to assess the safety and efficacy of centhaquine when added to the standard shock treatment. Centhaquine acts on specific receptors to improve blood flow and reduce vascular resistance, with prior studies showing promising effects on blood pressure, lactate levels, cardiac output, and mortality in animal models. Participants aged 18 years or older with hypovolemic shock and low systolic blood pressure 90 mmHg or lower will receive centhaquine intravenously at a dose of 0.01 mgkg body weight over one hour, in addition to standard care such as fluid resuscitation and vasopressors. A second dose may be given if blood pressure remains low, with no more than three doses in 24 hours and treatment continuing up to two days after enrollment. Each patient will receive between one and six doses within the first 48 hours. Throughout hospitalization, participants will be monitored closely until discharge or up to seven days after joining the trial. Researchers will assess safety by tracking adverse events and efficacy by measuring blood pressure, lactate levels, base deficit, ICU stay duration, ventilator use, urine output, mortality, organ dysfunction scores, respiratory distress, and neurological status. Statistical analyses will compare patient outcomes to understand centhaquines effects as an addition to standard hypovolemic shock treatment.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the Balanced Progressive Intensity Training BPIT 5-Line Principle, a 5-week supervised exercise program designed for healthy adults aged 18 to 65 years. The study focuses on how this training method influences functional movement efficiency, joint mobility, postural control, strength adaptation, and heart rate variability while tracking safety and individual responses to exercise intensity. Participants will engage in 3 to 5 supervised BPIT sessions per week, progressing through five levels of intensity based on anatomical landmarks and ground reaction forces. These levels include Ground-Based Low, Knee-Level Low-Moderate, Standing Moderate, Head-Level Moderate-High, and Plyometric High-Impact training. The entire program lasts five weeks, applying a structured increase in exercise challenge. Throughout the study, participants will undergo assessments at baseline and after five weeks, including functional movement screening, balance tests, strength measures, joint range of motion, and pain evaluation. Weekly monitoring will track resting heart rate variability and any training-related discomfort or minor injuries. The study aims to measure improvements in movement efficiency and neuromuscular adaptation while ensuring participant safety during the training period.